Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 15, 1999Canadian Journal of Physiology and Pharmacology

Functional involvement of angiotensin AT2receptor in adrenal catecholamine secretion in vivo

View Full Paper
Ask AI
Bookmark
Share

Population

anesthetized dogs

Comparison

Local administration of angiotensin II to the… vs Basal state and AngII administration alone

Design

Preclinical

Authors

DMDaniel MartineauUniversité de MontréalSLStéphane LamoucheUniversité de MontréalRBRichard BriandGeorgetown University

Discussion

Loading...

Member takes

Overview

AT2 receptors mediate adrenal catecholamine responses in vivo; leaves open translation to human cardiovascular disease or therapy.

Structured PICO

P
Population
anesthetized dogs
I
Intervention
Local administration of angiotensin II (AngII) (0.05 µg, 0.1 µM) to the left adrenal gland in the presence of AT2 receptor ligands PD 123319 (0.085 µg to 8.5 µg) or CGP 42112 (0.005 µg to 5 µg)
C
Comparator
Basal state and AngII administration alone
O
Outcome
Adrenal gland catecholamine (epinephrine and norepinephrine) outputsurrogate

AT2 receptors play a functional role in mediating catecholamine secretion by the adrenal medulla in response to AngII in vivo.

Cite This Study

Martineau et al. (1999) studied this question.

synapsesocial.com/papers/6a71abd45d37378ac1dec2dchttps://doi.org/10.1139/y99-037
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Distribution and functional significance of angiotensin-II AT1-AND AT2-Receptor subtypes in the rat adrenal gland1998 · 53 citations
  2. 2Angiotensin II Receptor Subtypes1992 · 228 citations
  3. 3Characterization of angiotensin II receptor subtypes in rat heart.1992 · 233 citations
  4. 4Angiotensin II stimulates the release of phospholipid-derived second messengers through multiple receptor subtypes in heart cells.1994 · 129 citations
  5. 5Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials1996 · 177 citations